Arcutis Biotherapeutics, Inc. Common Stock (ARQT) Financials
Key financial figures for Arcutis Biotherapeutics, Inc. Common Stock (Q2 2026).
Arcutis Biotherapeutics, Inc. reported revenue of $129.9 million for Q2 FY2026, up 59.3% from the same period a year earlier. Net income was $15.0 million, or $0.11 per share. Operating margin came to 12.65%, against -17.93% a year earlier. Free cash flow for the period was $12.5 million. Across the last 5 reported quarters, quarterly revenue has risen from $81.5 million in Q2 FY2025 to $129.9 million in Q2 FY2026. The figures above are as filed, and the full income statement, balance sheet and cash flow history for Arcutis Biotherapeutics, Inc. are on the SentiSense financials page.
- Revenue
- $130M
- Net Income
- $15M
- EPS
- $0.11
- Total Assets
- $489M
- Operating Cash Flow
- $13M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q2 FY2026 | $130M | $15M | $0.11 | 12.65% | $12M |
| Q1 FY2026 | $105M | -$11M | -$0.09 | -8.62% | $2M |
| Q4 FY2025 | $130M | $17M | $0.13 | 14.2% | $26M |
| Q3 FY2025 | $99M | $7M | $0.06 | 8.59% | -$2M |
| Q2 FY2025 | $82M | -$16M | -$0.13 | -17.93% | $246K |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $376M | -$16M | -$0.13 | -3.25% | -$6M |
| FY2024 | $197M | -$140M | -$1.16 | -65.33% | -$112M |
| FY2023 | $60M | -$262M | -$3.78 | -404.49% | -$247M |
Frequently asked questions
What was Arcutis Biotherapeutics, Inc.'s revenue last quarter?
Arcutis Biotherapeutics, Inc. reported revenue of $129.9 million for Q2 FY2026, up 59.3% from the same period a year earlier.
Is Arcutis Biotherapeutics, Inc. profitable?
Yes. Arcutis Biotherapeutics, Inc. reported net income of $15.0 million for Q2 FY2026, a net margin of 11.56% on revenue.
How has Arcutis Biotherapeutics, Inc.'s margin trended?
Operating margin was 12.65% in Q2 FY2026, compared with -17.93% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Arcutis Biotherapeutics, Inc. generate?
Arcutis Biotherapeutics, Inc. generated free cash flow of $12.5 million in Q2 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Arcutis Biotherapeutics, Inc. Common Stock on SentiSense, with up to forty quarters and twenty fiscal years of history.